Adam Wolff, MD
Neurology · Denver, CONPI 1053349597
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $222,523 of the $364,117 with a category attached, or 61.1%. 60 manufacturers reported payments, led by Eisai Inc. at 54.6% of the total. 2025 is the largest year on record at $170,882, more than ten times the $10,273 reported in 2019. Among neurology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,765 payments — averaging $131.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$199K
- Lilly USA, LLC$81K
- Biogen$15K
- E.r. Squibb & Sons, L.L.C.$13K
- Neurocrine Biosciences, Inc.$8K
- AbbVie$7K
- plus $40K from 54 others
Across 82 payments — averaging $24,945 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1.1M
- Novartis$760K
- AbbVie$135K
- Sanofi$21K
- Avanir Pharmaceuticals, Inc.$9K
- Bristol Myers Squibb$8K
- plus $6K from 2 others
What the payments were for
- Consulting fees$51,83714%
- Speaking & faculty fees$222,52361%
- Travel & lodging$38,23511%
- Food & beverage$51,46514%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$364,117 in reported general payments places this provider in the 95th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammakedImmune Globul G/Gly/Iga Avg 46 | 100 | $929,754 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 49 | $455,280 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 111 | $447,767 |
| Kesimpta PenOfatumumab | 21 | $178,336 |
| NuplazidPimavanserin Tartrate | 23 | $123,573 |
| AustedoDeutetrabenazine | 12 | $81,404 |
| BotoxOnabotulinumtoxina | 39 | $48,775 |
| Emgality PenGalcanezumab-Gnlm | 22 | $21,398 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 29 | $20,925 |
| Dihydroergotamine Mesylate | 16 | $20,586 |
| FycompaPerampanel | 16 | $19,860 |
| NuedextaDextromethorphan Hbr/Quinidine | 13 | $15,553 |
| Nurtec OdtRimegepant Sulfate | 14 | $14,725 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 169 | $9,471 |
| Pyridostigmine Bromide | 21 | $6,632 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $275 | $447,767111 claims |
| Acadia Pharmaceuticals IncNuplazid | $1,468 | $123,57323 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,172 | $81,40412 claims |
| AbbVieBotox | $6,994 | $48,77539 claims |
| Eisai Inc.Fycompa | $198,978 | $19,86016 claims |
| PfizerNurtec Odt, Dilantin | $1,132 | $19,06930 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $219 | $6,63221 claims |
| Upsher-smith Laboratories LLCTopiramate | $106 | $75020 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 334 neurology providers in Colorado.
Other neurology in Denver
- Justin MoonDenver$1.4M
- Michael AmentDenver$457K
- Shankar PerumalDenver$61K
- Jinny TaveeDenver$58K
- Alexander FeldmanDenver$28K
- James McNuttDenver$27K
- Jared YarnellDenver$27K
- Ralph RoundDenver$26K
- Jonathan DatarDenver$25K
- Tamara MillerFort Collins$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.